Watch our webinar with Argenica Therapeutics, featuring Managing Director Dr. Liz Dallimore. An interview followed by live Q&A with the audience.

Argenica Therapeutics Limited (ASX:AGN) is developing novel neuroprotective therapeutics to reduce brain damage after stroke and other devastating brain injuries. In June 2021, the Company listed on the ASX, and has since completed a successful Phase 1 clinical trial proving the safety and tolerability of its drug in healthy human volunteers, and is currently dosing acute ischaemic stroke patients in a Phase 2 clinical trial in Australia. The Company has a favourable competitive landscape and commercial opportunity, with no other universal marketed drugs available to protect brain cells from death following stroke.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.